Skip to main content
Equibles
ACAD logo

ACAD · Acadia Pharmaceuticals Inc

Track ACAD — free

Use ACAD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACAD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.75 +0.61 (+3.36%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.24B
Shares
172.83M
Volume · Nov 13 1.79M Avg daily vol (3M) 2.15M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$18.75 Open$18.12 Day$18.00–18.76 52W close$16.50–30.57 Avg vol 30d2.4M Short int8.3M · 4.8% of shares · 5.9d Short vol42% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Next earnings call
Jan 4, 2027 Est · unconfirmed · in 7 wks
Q3 2026 earnings call transcript
call held Nov 4, 2026
Play latest call

Latest documents

2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Sales rise to $918.3 million; Phase 3 continues

Acadia Pharmaceuticals reported nine-month net product sales of $918.3 million versus $787.5 million, with DAYBUE products at $366.1 million and NUPLAZID at $552.2 million. It continues two Phase 3 studies using a once daily 60 mg dose.

Revenue $342.29M ▲ 22.8% Net income $53.52M ▼ 25.4% Diluted EPS $0.31 ▼ 26.2%
Read from the MD&A section
4 source passages
Net product sales, comprised of NUPLAZID and DAYBUE products, were $918.3 million and $787.5 million for the nine months ended September 30, 2026 and 2025, respectively. Net product sales of NUPLAZID were $552.2 million and $505.7 million for the nine months ended September 30, 2026 and 2025, respectively. Net product sales of DAYBUE products were $366.1 million and $281.8 million for the nine months ended September 30, 2026 and 2025, respectively. Therefore, we plan to continue enrolling our two ongoing Phase 3 studies evaluating remlifanserin for the once daily 60 mg dose in ADP while implementing amendments to the Phase 3 program, including removing the once daily 30 mg dosage arm. Open the document at this passage
Nov 4
Current report 8-K
Third-quarter revenue rises as DAYBUE guidance increases

Acadia Pharmaceuticals Inc. reported third-quarter 2026 GAAP total revenues of $342 million, up 23% year-over-year, and raised 2026 DAYBUE global net product sales guidance to $505 to $520 million from $480 to $510 million.

Financial results
3 source passages
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. GAAP total revenues, consisting of net product sales from NUPLAZID and DAYBUE, were $342 million in the third quarter of 2026, up 23% as compared to GAAP total revenues of $279 million in the third quarter of 2025, and up 22% as compared to non-GAAP adjusted total revenues of $281 million in the third quarter of 2025. DAYBUE (including all forms of trofinetide) global net product sales in the range of $505 to $520 million, up from the previous range of $480 to $510 million. Open the document at this passage
Oct 23
Current report 8-K
Director or officer change, or executive pay

Acadia Pharmaceuticals Inc. said Elizabeth H.Z. Thompson, Ph.D., ended her employment and Head of Research and Development role effective October 23, 2026, will consult through December 31, 2026, and is seeking her replacement.

Sep 24
Current report 8-K
Regulation FD disclosure, Other events

Acadia Pharmaceuticals Inc. reported that once daily 60 mg remlifanserin narrowly missed the SAPS-H+D primary endpoint at week 6 (p=0.0603), showed nominal significance on CGI-S-ADP (p=0.0077), and will continue two Phase 3 studies while removing the 30 mg arm.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.20B
Trailing 12 months
Net income (TTM)
$362.23M
Trailing 12 months
Revenue growth YoY
+22.8%
Year over year
Operating margin
10.2%
Trailing 12 months
P / E (TTM)
8.8
Trailing earnings · reciprocal yield 11.3%
FCF yield
2.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$322.37M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.8%
Year over year · more shares
Price change (1Y)
-20.7%
Trailing year
Short interest
4.8%
Latest settlement · 5.9 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲12.4% $259.60M $143.74M '24 Q4* ▲18.7% $244.32M $18.99M '25 Q1 ▲9.3% $264.57M $26.67M '25 Q2 ▲11.3% $278.63M $71.78M '25 Q3 ▲9.4% $283.99M $273.57M '25 Q4* ▲9.7% $268.06M $3.64M '26 Q1 ▲16.4% $307.96M $31.50M '26 Q2 LATEST ▲22.8% $342.29M $53.52M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −14%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 16%
mid-range
Momentum
relative strength
Very Weak
1-month return −2%
trailing
6-month return −12%
trailing
YTD return −30%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $22 › 200d $23 — 200d above 50d
Institutional flow Accumulating
307 of 355 funds reported for Sep 30 · net +638.9K sh shares · +42 new
Insider flow Distributing
Net -$69.3K over 90 days · 100% sells
Short interest Falling
4.81% of shares out · ▼ -8.5% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
355 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Excellent
Revenue growth +40%
Y/Y
Gross margin 94%
contracting
EPS growth +69%
Y/Y
Free cash flow $105.1M
Valuation P/E 8.8
below peers
Balance sheet $177.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −46%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the Earnings Call filed Aug 4, 2026
Total 2026 revenue · full year 2026 Raised $1.24B – $1.3B
May 6, 2026 $1.22B – $1.28B changed to Aug 4, 2026 $1.24B – $1.3B
prior FY $1.07B midpoint +18.5% Y/Y
Gross to net · full year 2026 23% – 25%
R&d expenses · full year 2026 $355M – $380M
DAYBUE net sales · full year 2026 Raised $480M – $510M
Feb 25, 2026 $460M – $490M changed to Aug 4, 2026 $480M – $510M
NUPLAZID net sales · full year 2026 $760M – $790M
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

DAYBUE net product sales · Full Year 2026 $460M – $490M
Prior guidance period ended · from the 8-K filed Jan 13, 2026
Net sales · 2025 at least $1B
Guided vs delivered · last 4 settled
Total Revenues (U.S. only) full year 2025
guided $1.05B – $1.1B
$1.07B In line
Total revenue Full Year 2024
guided $930M – $980M
$957.8M In line
Net sales for the year
guided $480M – $515M
$484.15M In line
Net sales full year 2020
guided $430M – $450M
$441.76M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $22 › 200d $23 — 200d above 50d
Institutional flow Accumulating
307 of 355 funds reported for Sep 30 · net +638.9K sh shares · +42 new
Insider flow Distributing
Net -$69.3K over 90 days · 100% sells
Short interest Falling
4.81% of shares out · ▼ -8.5% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
355 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $17 Now $19 · 16% Range high $31
vs 200-day avg -20% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
DAYBUE net product sales 125M the second quarter of 2026 —
Non-GAAP Adjusted NUPLAZID Net Sales non-GAAP 183.2M 2Q26 —
GAAP → non-GAAP reconciliation
GAAP GAAP NUPLAZID Net Sales 183.2M
+0M Allocation of 2025 Amount
= Non-GAAP Adjusted NUPLAZID Net Sales 183.2M
Non-GAAP Adjusted Total Revenues non-GAAP 308M 2Q26 —
GAAP → non-GAAP reconciliation
GAAP Non-GAAP Adjusted NUPLAZID Net Sales 183.2M
+124.8M DAYBUE products Net Sales
= Non-GAAP Adjusted Total Revenues 308M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACAD
Acadia Pharmaceuticals Inc
this stock
$3.24B -29.8% +40.4% 8.8 4.8%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
360
% held
98.3%
Reported
307 of 355
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
326
View
Short & Settlement
Short Interest Falling
Shares short
8.3M
Days to cover
5.9d
Change
-776.8K sh
View
Short Volume
Short vol %
42%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
6.8K
Value
$172.0K
As of
Sep 24, 2026
View
Off-Exchange
Off-exchange %
32.7%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$69.3K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Jun 16, 2022
View
Financials
Financials
Revenue (FY)
$1.1B
Net income (FY)
$391.0M
EPS diluted
$2.30
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
20

Acadia Pharmaceuticals reported nine-month net product sales of $918.3 million versus $787.5 million, with DAYBUE products at $366.1 million and NUPLAZID at $552.2 million. It continues two Phase 3 studies using a once daily 60 mg dose.

View
Proposed Sales
Value
$158.8K
Shares
5.8K
Filed
Aug 5, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 17, 2026
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Acadia Pharmaceuticals Comments o…
Published
Nov 10, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
ACAD -11.7% -1.9% -11.8% -8.9% -29.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -14.3% -0.8% -12.3% -8.8% -40.4%
Key facts CIK 1070494 CUSIP 004225108 13F (30d) 265 filings 249 filers Visit website Investor relations